Wealth Effects’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,891,917
| Closed | -$40.8M | – | 240 |
|
|
2025
Q4 | $40.8M | Sell |
1,891,917
-396,896
| -17% | -$7.71M | 12.75% | 1 |
|
|
2025
Q3 | $35M | Sell |
2,288,813
-66,009
| -3% | -$859K | 11.24% | 1 |
|
|
2025
Q2 | $20.8M | Sell |
2,354,822
-14,300
| -0.6% | -$126K | 7.8% | 2 |
|
|
2025
Q1 | $18.6M | Buy |
2,369,122
+24,992
| +1% | +$209K | 7.79% | 3 |
|
|
2024
Q4 | $24.6M | Buy |
2,344,130
+110,359
| +5% | +$1.34M | 8.75% | 2 |
|
|
2024
Q3 | $29.3M | Sell |
2,233,771
-34,084
| -2% | -$519K | 10.26% | 1 |
|
|
2024
Q2 | $31.9M | Buy |
2,267,855
+3,629
| +0.2% | +$59.2K | 11.56% | 1 |
|
|
2024
Q1 | $38.2M | Sell |
2,264,226
-152,100
| -6% | -$2.27M | 14.11% | 1 |
|
|
2023
Q4 | $34.1M | Buy |
2,416,326
+7,037
| +0.3% | +$82.7K | 12.83% | 1 |
|
|
2023
Q3 | $24.8M | Buy |
2,409,289
+40,200
| +2% | +$538K | 12.25% | 1 |
|
|
2023
Q2 | $39M | Sell |
2,369,089
-129,749
| -5% | -$1.69M | 17.18% | 1 |
|
|
2023
Q1 | $22.9M | Sell |
2,498,838
-16,067
| -0.6% | -$132K | 11.72% | 1 |
|
|
2022
Q4 | $18M | Sell |
2,514,905
-79,855
| -3% | -$560K | 10.28% | 1 |
|
|
2022
Q3 | $13M | Buy |
2,594,760
+10,670
| +0.4% | +$58.7K | 7.95% | 2 |
|
|
2022
Q2 | $6.3M | Buy |
2,584,090
+206,800
| +9% | +$849K | 3.79% | 3 |
|
|
2022
Q1 | $16.2M | Buy |
2,377,290
+72,273
| +3% | +$497K | 7.58% | 2 |
|
|
2021
Q4 | $18.6M | Buy |
+2,305,017
| New | +$21.1M | 7.73% | 2 |
|
Other funds holding AVDL
Wealth Effects's AVDL Position: Q1 2026 in Review
Wealth Effects sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,891,917 shares — an estimated $40.8M sold.
Wealth Effects first reported a position in AVDL in Q4 2021 and held it in 17 quarters. The position peaked at $40.8M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Wealth Effects reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Wealth Effects sold 1,891,917 Avadel Pharmaceuticals shares in Q1 2026, an estimated $40.8M.
- Wealth Effects first reported a position in Avadel Pharmaceuticals in Q4 2021 and held it in 17 quarters.
- Wealth Effects's Avadel Pharmaceuticals position peaked at $40.8M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Wealth Effects's 13F filing for Q1 2026, filed 21 Apr 2026.